MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

282.40
+5.83
+2.11%
Closed 19:48 09/25 EDT
OPEN
277.35
PREV CLOSE
276.57
HIGH
282.40
LOW
274.47
VOLUME
246.27K
TURNOVER
--
52 WEEK HIGH
282.40
52 WEEK LOW
114.41
MARKET CAP
25.53B
P/E (TTM)
-13.0933
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 2d ago
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 3d ago
Leap Therapeutics/BeiGene initiates DKN-01+tislelizumab combination mid-stage study in gastric cancer
Leap Therapeutics (LPTX) up 7.2% in premarket, and BeiGene, (BGNE) have announced that first patient has been dosed in the DisTinGuish Phase 2a trial, evaluating Leap's DKN-01, in combination with latter's tislelizumab, with
Seekingalpha · 6d ago
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, Ltd., (Nasdaq:BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced
PR Newswire · 6d ago
3 Top Biotech Picks for 2025
MotleyFool.com · 09/20 07:32
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
BeiGene presents promising tislelizumab and pamiparib data in lung and ovarian cancer
BeiGene (BGNE) announces the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a first-line treatment for patients with
Seekingalpha · 09/18 10:41
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene presents Phase 3 data of tislelizumab in non-squamous non-small cell lung cancer and Phase 2 data of pamiparib in ovarian cancer at ESMO 2020.
Business Wire · 09/17 23:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BGNE. Analyze the recent business situations of BeiGene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BGNE stock price target is 237.90 with a high estimate of 280.00 and a low estimate of 175.00.
EPS
Institutional Holdings
Institutions: 306
Institutional Holdings: 53.34M
% Owned: 59.00%
Shares Outstanding: 90.40M
TypeInstitutionsShares
Increased
94
2.02M
New
51
146.60K
Decreased
64
962.79K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
John Oyler
President/General Manager
Xiaobin Wu
Co-Founder/Non-Executive Director
Xiaodong Wang
Chief Financial Officer
Howard Liang
Other
Eric Hedrick
Other
Jane Huang
Secretary
Hing Ling Chau
Non-Executive Director
Anthony Hooper
Non-Executive Independent Director
Timothy Chen
Non-Executive Independent Director
Donald Glazer
Non-Executive Independent Director
Michael Goller
Non-Executive Independent Director
Ranjeev Krishana
Non-Executive Independent Director
Thomas Malley
Non-Executive Independent Director
Corazon Sanders
Non-Executive Independent Director
Jing-Shyh Su
Non-Executive Independent Director
Qingqing Yi
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BGNE
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Beigene Ltd (ADR) stock information, including NASDAQ:BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.